Health Economics

Impact

As a cardiologist, health economist, and outcomes researcher, the overarching goal of Dr. Kazi’s clinical and research efforts is to use real world data on safety, effectiveness, and cost to improve long-term cardiovascular health outcomes in the US and overseas.

Nationally, Dr. Kazi has advocated for increased access to effective and safe drugs, devices, and diagnostic tests by highlighting issues related to cost-effectiveness and affordability. For instance, his work on the PCSK9 inhibitors (including 6 publications, 2 public reports, and more than a dozen presentations) has been credited with improving access to these effective, safe, but previously unaffordable therapies. Dr. Kazi’s work has been cited by ACC/AHA guidelines for lipid management, heart failure, and chronic coronary disease. Just as importantly, Dr. Kazi’s work continues to be cited by policy makers, including in reports from the US Department of Health and Human Services to the US Congress and in publications from the Centers for Disease Control and Prevention. Our research group continues to evaluate new technologies and programs, including rare disease drugs, devices, and public health initiatives.

Globally, Dr. Kazi has used rigorous cost-effectiveness analyses to draw attention to neglected diseases such as rheumatic heart disease and underused therapies like secondary prevention drugs for coronary disease and ischemic stroke. Dr. Kazi routinely guides professional societies and non-governmental organizations in the role of economic evaluations to improve cardiovascular outcomes in low- and middle-income countries. Our group’s commitment to monitoring clinical outcomes, costs, and unintentional consequences of any interventions we develop has been the unifying thread that runs through the Health Economics Section’s body of work.